FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: Comparison with physostigmine

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 3, 1997, Pages 1201-1209

  Matsuoka, Nobuya ^b   Aigner, Thomas G ^a,c  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b ASTELLAS PHARMA INC   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; NEUROTROPIC AGENT; PHYSOSTIGMINE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; DEMENTIA; DRUG EFFECT; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VISUAL MEMORY;

ANIMALS; BENZAMIDES; CHOLINESTERASE INHIBITORS; DEMENTIA; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; MACACA MULATTA; MUSCARINIC ANTAGONISTS; NOOTROPIC AGENTS; PHYSOSTIGMINE; PIPERAZINES; RECEPTORS, N-METHYL-D-ASPARTATE; SCOPOLAMINE; VISUAL PERCEPTION;

EID: 0030947805     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. AIGNER, T. G. AND MISHKIN, M.: The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav. Neural. Biol. 45: 81-87, 1986.
2. AIGNER, T. G., MITCHELL, S. J., AGGLETON, J. P., DELONG, M. R., STRUBLE, R. G., PRICE, D. L., WENK, G. L. AND MISHKIN, M.: Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 92: 292-300, 1987.
3. AIGNER, T. G., MITCHELL, S. J., AGGLETON, J. P., DELONG, M. R., STRUBLE, R. G., PRICE, D. L., WENK, G. L., PETTIGREW, K. D. AND MISHKIN, M.: Transient impairment of recognition memory following ibotenic-acid lesions of the basal forebrain in macaques. Exp. Brain Res. 86: 18-26, 1991.
4. ARAUJO, D. M., LAPCHAK, P. A., COLLIER, B. AND QUIRION, R.: Evidence that somatostatin enhances endogenous acetylcholine release in the rat hippocampus. J. Neurochem. 55: 1546-1555, 1990.
5. BISCHOFF, C. AND TIKDTKE, P. I.: Competitive and non-competitive NMDA receptor antagonists in spatial learning tasks. Eur. J. Pharmacol. 213: 269-273, 1992.
6. BLISS, T. V. P. AND COLLINGRIDGE, G. L.: A synaptic model of memory: Long-term potentiation in the hippocampus. Nature (Lond.) 361: 31-39, 1993.
7. COLLINGRIDGE, G. L., KEHL, S. J. AND MCLENNAN, H.: Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J. Physiol. (Lond.) 334: 33-46, 1983.
8. COLLINGRIDGE, G. L. AND LESTER, R. A. J.: Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 40: 143-210, 1989.
9. COYLE, J. T., PRICE, D. L. AND DELONG, M. R.: Alzheimer's disease: A disorder of cholinergic innervation. Science (Wash. DC) 219: 1184-1190, 1983.
10. DAVIES, P., KATZMAN, R. AND TERRY, R. D.: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature (Lond.) 288: 279-280, 1980.
11. DAVIES, P, AND MALONEY, A. J. F.: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403, 1976.
12. DUNNETT, S. B. AND FIBIGER, H. C.: Role of forebrain cholinergic systems in learning and memory: Relevance to the cognitive deficits of aging and Alzheimer's dementia. Prog. Brain Res. 98: 413-420, 1993.
13. EPELBAUM, J.: Somatostatin in the central nervous system: Physiology and pathological modifications. Prog. Neurobiol. 27: 63-100, 1986.
14. EPELBAUM, J., DOURNAUD, P., FODOR, M. AND VIOLLET, C.: The neurobiology of somatostatin. Crit. Rev. Neurobiol. 8: 25-44, 1994.
15. FITTEN, L. J., PERRYMAN, K. M., GROSS, P. L., FINE, H., CUMMINS, J. AND MARSHALL, C.: Treatment of Alzheimer's disease with short-and long-term oral THA and lecithin: A double blind study. Am. J. Psychiatry 147: 239-242, 1990.
16. FLOOD, J. F. AND CHERKIN, A.: Scopolamine effects on memory retention in mice: A model of dementia? Behav. Neural Biol. 45: 169-184, 1986.
17. GREENAMYRE, J. T. AND YOUNG, A. B.: Excitatory amino acids and Alzheimer's disease. Neurobiol. Aging 10: 593-602, 1989.
18. HAROUTUNIAN, V., BARNES, E. AND DAVIS, K. L.: Cholinergic modulation of memory in rats. Psychopharmacology 87: 266-271, 1985.
19. JOHANSSON, O., HOKFELT, T. AND ELDE, R. P.: Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience 13: 265-339, 1984.
20. MAEDA, N., MATSUOKA, N., YAMAZAKI, M., ARAKAWA, H., OHKUBO, Y. AND YAMAGUCHI, I.: A screening concept based on a hypothesis led to the development of a putative cognitive enhancer that stimulates penile erection. Jpn. J. Pharmacol. 64: 147-153, 1994.
21. MATSUOKA, N. AND AIGNER, T. G.: D-Cycloserine, a partial agonist at the glycine site coupled to NMDA receptors, improves visual recognition memory in rhesus monkeys. J. Pharmacol. Exp. Ther. 278: 891-897, 1996a.
22. MATSUOKA, N. AND AIGNER, T. G.: Cholinergic-glutamatergic interactions in visual recognition memory of rhesus monkeys. NeuroReport 7: 565-568, 1996b.
23. MATSUOKA, N., KANEKO, S. AND SATOH, M.: Somatostatin augments long-term potentiation of the mossy fiber-CA3 system in guinea-pig hippocampal slices. Brain Res. 553: 188-194, 1991.
24. MATSUOKA, N., MAEDA, N., YAMAGUCHI, I. AND SATOH, M.: Possible involvement of brain somatostatin in the memory formation of rats and the cognitive enhancing action of FR121196 in passive avoidance task. Brain Res. 642: 11-19, 1994.
25. MATSUOKA, N., MAEDA, N., YAMAZAKI, M., OHKUBO, Y. AND YAMAGUCHI, I.: Effects of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks. J. Pharmacol. Exp. Ther. 263: 436-444, 1992.
26. MATSUOKA, N., YAMAGUCHI, I. AND SATOH, M.: Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur. J. Pharmacol. 241: 27-34, 1993.
27. MATSUOKA, N., YAMAZAKI, M. AND YAMAGUCHI, I.: Changes in brain somatostatin in memory deficient rats: Comparison with cholinergic markers. Neuroscience 66: 617-626, 1995.
28. MCENTEE, W. J. AND CROOK, T. H.: Glutamate: Its role in learning, memory, and the aging brain. Psychopharmacology 111: 391-401, 1993.
29. MOLCHAN, S. E., MARTINEZ, R. A., HILL, J. L., WEINGARTNER, H. J., THOMPSON, K., VITIELLO, B. AND SUNDERLAND, T.: Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res. Rev. 17: 215-226, 1992.
30. MORRIS, R. G. M., ANDERSON, E., LYNCH, G. S. AND BAUDRY, M.: Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature (Lond.) 319: 774-776, 1986.
31. NAKANISHI, S.: Molecular diversity of glutamate receptors and implications for brain function. Science (Wash. DC) 258: 597-603, 1992.
32. OGURA, H. AND AIGNER, T. G,: MK-801 impairs recognition memory in rhesus monkeys: Comparison with cholinergic drugs. J. Pharmacol. Exp. Ther. 266: 60-64, 1993.
33. PALMER, A. M. AND GERSHON, S.: Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 4: 2745-2752, 1990.
34. PERRY, E. K., TOMLINSON, B. E., BLESSED, G., BERGMANN, K., GIBSON, P. H. AND PERRY, R. H.: Correlation of cholinergic abnormalities with senile Plaques and mental test scores in senile dementia. Br. Med. J. 2: 1457-1459, 1978.
35. PETERSEN, R.: Scopolamine induced learning failures in man. Psychopharmacology 52: 283-289, 1977.
36. 3H]MK-801 binding in Alzheimer's disease. J. Neurochem. 53: 698-704, 1989.
37. RIDLEY, R. M. AND BAKER, H. F.: A critical evaluation of monkey models of amnesia and dementia. Brain Res. Rev. 16: 15-37, 1991.
38. RUPNIAK, N. M., STEVENTON, M. J., FIELD, M. J., JENNINGS, C. A. AND IVERSEN, S. D.: Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 99: 189-195, 1989.
39. SAGAR, S. M., LANDRY, D., MILLABD, W. J., BADGER, T. M., ARNOLD, M. A. AND MARTIN, J. B.: Depletion of somatostatin-like immunoreactivity in the rat central nervous system by cysteamine. J. Neurosci. 2: 225-231, 1982.
40. SAHGAL, A.: Some limitations of indices derived from signal detection theory: Evaluation of an alternative index for measuring bias in memory tasks. Psychopharmacology 91: 517-520, 1987.
41. SITARAM, N.: Cholinergic hypothesis of human memory: Review of basic and clinical studies. Drug Dev. Res. 4: 481-488, 1984.
42. TEYLER, T. J. AND DISCENNA, P.: Long-term potentiation as a candidate mnemonic device. Brain Res. Rev. 7: 15-28, 1984.
43. WENK, G. L.: A primate model of Alzheimer's disease. Behav. Brain Res. 57: 117-122, 1993.
44. WHISHAW, I. Q. AND AUER, R. N.: Immediate and long-lasting effects of MK-801 on motor activity, spatial navigation in a swimming pool and EEG in the rat. Psychopharmacology 98: 500-507, 1989.
45. YAMAZAKI, M., MATSUOKA, N., MAEDA, N., OHKUBO, Y. AND YAMAGUCHI, I.: FK960, N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate, ameliorates the memory defects in rats through a novel mechanism of action. J. Pharmacol. Exp. Ther., 279: 1157-1173, 1996.
46. YLINEN, A., LAHTINEN, H., SIRVIO, J., PARTANEN, J., ASIKAINEN, A., GULYAS, A., FREUND, T. F. AND RIEKKINEN, P.: Behavioural, electrophysiological and histopathological changes following sustained stimulation of the perforant pathway input to the hippocampus: Effect of the NMDA receptor antagonist, CGP 39551. Brain Res. 553: 195-200, 1991.